The spray works by killing the virus in the upper airways, which then prevents further spread to the lungs and incubation. The treatment uses nitric oxide (NO), which is a natural nanomolecule that can be produced by the human body. NO is a well-established anti-microbial that has demonstrated a clear impact on SARS-CoV-2. Additionally, the pharmacology, toxicity, and safety data for NO use in humans has been known for decades, which has allowed it to be a safe treatment method for use in newborn babies as well as adults. Specifically, the NO molecule used in the novel spray is identical to the molecule that has been used to treat persistent pulmonary hypertension in newborn babies. Following the release of the phase 2 clinical data from the UK, the earlier phase 2 Canadian trials, and independent lab tests conducted at the Antiviral Research Institute at Utah State University, SaNOtize is applying for emergency use authorization to regulatory authorities in the UK and Canada currently.